Cytek Biosciences Inc (CTKB) — Cash Flow Reinvestment Rate

Latest as of June 2025: 166.57x

Cytek Biosciences Inc (CTKB) has a Cash Flow Reinvestment Rate of 166.57x as of June 2025, reinvesting $17.99 Million (capex $1.58 Million plus investments $-16.41 Million) from operating cash flow of $108.00K. See how much free cash does Cytek Biosciences Inc generate to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

166.57x
(Capex + Investments) / Operating CF

Total Reinvested

$17.99 Million
Capex + Investments

Operating Cash Flow

$108.00K
USD

Capital Expenditures

$1.58 Million
USD

Cytek Biosciences Inc Cash Flow Reinvestment Rate (2020–2024)

Historical reinvestment intensity for Cytek Biosciences Inc across 4 annual periods. For the full cash flow conversion analysis, see CTKB cash generation efficiency.

Annual Cash Flow Reinvestment Rate for Cytek Biosciences Inc (2020–2024)

Year-by-year capital reinvestment analysis for Cytek Biosciences Inc. See Cytek Biosciences Inc (CTKB) financial flexibility to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2024 3.41x $86.50 Million $25.38 Million $3.52 Million ▼ -89.9%
2023 33.87x $178.85 Million $5.28 Million $4.83 Million ▲ +518.4%
2021 5.48x $25.36 Million $4.63 Million $4.36 Million ▲ +2582.8%
2020 0.20x $3.09 Million $15.16 Million $1.55 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow